Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Aura Biosciences, Inc. (AURA)
|
Add to portfolio |
|
|
|
| Price: |
$18.94
| | Metrics |
| OS: |
38.2
|
M
| |
-43
|
% ROE
|
| Market cap: |
$723
|
M
| |
-57
|
% ROIC
|
|
Net cash:
|
$162
|
M
| |
$4.24
|
per share
|
|
EV:
|
$561
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($79.6)
|
M
| |
|
|
| EPS |
($1.90)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-05-22 | Dec-31-21 | Dec-05-21 | Dec-31-20 | Dec-31-19 |
| Revenues | 0.0 | 42.2 | 0.0 | 25.2 | 0.0 | 0.0 |
| Revenue growth | | 67.9% | | | | |
| Cost of goods sold | -120.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 120.3 | 42.2 | 0.0 | 25.2 | 0.0 | 0.0 |
| Gross margin | -1336255.6% | 100.0% | | 100.0% | | |
| Research and development | 42.2 | | 25.2 | | 18.0 | 19.6 |
| General and administrative | 18.1 | 18.1 | 10.1 | 10.1 | 4.2 | 4.5 |
| EBIT | -60.6 | -60.9 | -35.3 | -35.3 | -22.2 | -24.2 |
| EBIT margin | 673477.8% | -144.3% | | -140.1% | | |
| Pre-tax income | -58.8 | -58.8 | -35.3 | -35.3 | -22.2 | 0.0 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net income | -58.8 | -58.8 | -35.3 | -35.3 | -22.2 | 0.0 |
| Net margin | 652922.2% | -139.1% | | -140.1% | | |
| |
| Diluted EPS | ($1.96) | $0.00 | ($6.83) | ($0.01) | ($60.47) | $0.00 |
| Shares outstanding (diluted) | 29.9 | 29,937.2 | 5.2 | 5,160.0 | 0.4 | 338.3 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|